Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte CEO Grant Pickering sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 1, 2024, Grant Pickering, the CEO of Vaxcyte, Inc. (PCVX), sold 1,308 shares of common stock at a weighted-average price of approximately $78.80 and another 1,308 shares at a weighted-average price of approximately $78.78.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following the transactions, Pickering directly owns 478,888 shares of Vaxcyte common stock.
• Additionally, he indirectly owns 142,130 shares through a trust for his daughter and another 142,130 shares through a trust for his son.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact due to the pre-planned nature of the transaction.

Key Dates